Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Serin · SciRah

Researcher profile · Semantic Scholar

D. Serin

Share profile

D. Serin — researcher profile on SciRah

h-index: 28
Works: 150
Citations: 4,144

Most-cited papers

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
H. Roche, P. Fumoleau, M. Spielmann, J. Canon +16 more
2006Journal of Clinical Oncology522 citations Open access
Semantic Scholar
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
X. Pivot, G. Romieu, M. Debled, J. Pierga +16 more
2013The Lancet Oncology332 citations
Semantic Scholar
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
É. Luporsi, F. André, F. Spyratos, Pièrre-Marie Martin +21 more
2011Breast Cancer Research and Treatment332 citations Open access
Semantic Scholar
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
P. Fumoleau, R. Largillier, C. Clippe, V. Diéras +11 more
2004European Journal of Cancer295 citations
Semantic Scholar
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
M. Spielmann, H. Roche, T. Delozier, J. Canon +16 more
2009Journal of Clinical Oncology270 citations
Semantic Scholar
Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases.
B. Cutuli, C. C. Le-Nir, D. Serin, Y. Kirova +13 more
2010Critical reviews in oncology/hematology188 citations
Semantic Scholar
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
B. Coudert, R. Largillier, L. Arnould, P. Chollet +11 more
2007Journal of Clinical Oncology140 citations
Semantic Scholar
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
X. Pivot, G. Romieu, M. Debled, J. Pierga +330 more
2019The Lancet117 citations Open access
Semantic Scholar
Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
J. Extra, É. Antoine, A. Vincent-Salomon, T. Delozier +13 more
2010The Oncologist116 citations Open access
Semantic Scholar
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
I. Fogelman, G. M. Blake, R. Blamey, M. K. Palmer +5 more
2003Osteoporosis International105 citations
Semantic Scholar
Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
P. Fumoleau, P. Kerbrat, P. Romestaing, P. Fargeot +16 more
2003Journal of Clinical Oncology105 citations
Semantic Scholar
Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study.
A. Tolédano, P. Garaud, D. Serin, A. Fourquet +6 more
2005International Journal of Radiation Oncology, Biology, Physics93 citations
Semantic Scholar
A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
J. Roüessé, B. de la Lande, F. Bertheault-Cvitkovic, D. Serin +12 more
2006International Journal of Radiation Oncology, Biology, Physics75 citations
Semantic Scholar
Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
A. Tolédano, D. Azria, P. Garaud, A. Fourquet +6 more
2007Journal of Clinical Oncology72 citations
Semantic Scholar
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
H. Roche, P. Kerbrat, J. Bonneterre, P. Fargeot +7 more
2006Annals of Oncology66 citations Open access
Semantic Scholar
Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer.
E. Brain, T. Bachelot, D. Serin, S. Kirscher +7 more
2005Journal of the American Medical Association (JAMA)47 citations
Semantic Scholar
Breast cancer, early stage
Tony S. K. Mok, L. Paz-Ares, Y.-L. Wu, S. Novello +496 more
201245 citations Open access
Semantic Scholar
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.
P. Piedbois, D. Serin, F. Priou, P. Laplaige +9 more
2006Annals of Oncology43 citations Open access
Semantic Scholar
Decision-making and breast cancer clinical trials: how experience challenges attitudes.
J. Mancini, J. Genève, F. Dalenc, D. Genre +9 more
2007Contemporary Clinical Trials38 citations
Semantic Scholar
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.
B. Coudert, B. Asselain, M. Campone, M. Spielmann +16 more
2012The Oncologist37 citations Open access
Semantic Scholar
Impact of organised programs on colorectal cancer screening
F. Eisinger, L. Cals, Anne Calazel-Benque, J. Blay +8 more
2008BMC Cancer37 citations Open access
Semantic Scholar
Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives.
J. Cautela, N. Lalevée, C. Ammar, S. Ederhy +12 more
2016International Journal of Cardiology35 citations
Semantic Scholar
Cancer screening in France: subjects’ and physicians’ attitudes
F. Eisinger, J. Blay, J. Morère, O. Rixe +8 more
2007Cancer Causes and Control34 citations Open access
Semantic Scholar
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial
J. Jacquemier, J. Boher, H. Roche, B. Esterni +11 more
2011Breast Cancer Research27 citations Open access
Semantic Scholar
[For a coordination of the supportive care for people affected by severe illnesses: proposition of organization in the public and private health care centres].
I. Krakowski, F. Boureau, R. Bugat, L. Chassignol +12 more
2004Bulletin du Cancer26 citations
Semantic Scholar
Breast cancer screening in France: results of the EDIFICE survey
Xavier Pivot, O. Rixe, J. Morère, Y. Coscas +7 more
2008International Journal of Medical Sciences24 citations Open access
Semantic Scholar
Does concurrent radiochemotherapy affect cosmetic results in the adjuvant setting after breast-conserving surgery? Results of the ARCOSEIN multicenter, Phase III study: patients' and doctors' views.
A. Tolédano, M. Bollet, A. Fourquet, D. Azria +8 more
2007International Journal of Radiation Oncology, Biology, Physics24 citations
Semantic Scholar
Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer
T. Petit, A. Benider, A. Yovine, P. Bougnoux +9 more
2006Anti-Cancer Drugs24 citations
Semantic Scholar
'Parcours de Femme 2001': a French opinion survey on overall disease and everyday life management in 1870 women presenting with gynecological or breast cancer and their caregivers.
D. Serin, J. Dilhuydy, P. Romestaing, N. Guiochet +4 more
2004Annals of Oncology20 citations Open access
Semantic Scholar
Development and feasibility of a set of quality indicators relative to the timeliness and organisation of care for new breast cancer patients undergoing surgery
M. Ferrua, M. Couralet, G. Nitenberg, S. Morin +2 more
2012BMC Health Services Research19 citations Open access
Semantic Scholar
A Multicenter Study to Assess a Systematic Screening of Occupational Exposures in Lung Cancer Patients
O. Pérol, N. Lepage, H. Noelle, P. Lebailly +13 more
2023International Journal of Environmental Research and Public Health18 citations Open access
Semantic Scholar
Assessment of care by breast cancer patients participating or not participating in a randomized controlled trial: a report with the Patients' Committee for Clinical Trials of the Ligue Nationale Contre le Cancer.
C. Julian-reynier, J. Genève, F. Dalenc, D. Genre +9 more
2007Journal of Clinical Oncology18 citations
Semantic Scholar
Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study
D. Serin, M. Verrill, A. Jones, T. Delozier +5 more
2005British Journal of Cancer18 citations Open access
Semantic Scholar
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
V. D'Hondt, J. Canon, L. Roca, C. Lévy +18 more
2019European Journal of Cancer15 citations Open access
Semantic Scholar
Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer
X. Pivot, G. Romieu, H. Bonnefoi, J. Pierga +16 more
201215 citations Open access
Semantic Scholar
[Physical activity and cancer survival].
I. Romieu, Marina Touillaud, Pietro Ferrari, Y. Bignon +14 more
2012Bulletin du Cancer14 citations
Semantic Scholar
A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000).
C. Delbaldo, D. Serin, M. Mousseau, S. Greget +9 more
2014European Journal of Cancer13 citations Open access
Semantic Scholar
ASSOCIATION BETWEEN TUMOR EGFR AND KRAS MUTATION STATUS AND CLINICAL OUTCOMES IN NSCLC PATIENTS RANDOMIZED TO SORAFENIB PLUS BEST SUPPORTIVE CARE ( BSC ) OR BSC ALONE : SUBANALYSIS OF THE PHASE III MISSION TRIAL
G. Romieu, H. Bonnefoi, J. Pierga, P. Kerbrat +29 more
201213 citations
Semantic Scholar
Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial.
B. Coudert, M. Campone, M. Spielmann, M. Symann +16 more
200913 citations
Semantic Scholar
Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer.
H. Roche, D. Allouache, G. Romieu, H. Bourgeois +16 more
200913 citations
Semantic Scholar
Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients
J. Kurtz, F. Rousseau, N. Meyer, T. Delozier +4 more
2008Oncology13 citations
Semantic Scholar
Safety analysis from PACS 04-A phase III trial comparing 6 cycles of FEC100 with 6 cycles of ET75 for node-positive early breast cancer patients, followed by sequential trastuzumab in HER2+ patients: Preliminary results.
M. Spielmann, H. Roche, T. Delozier, G. Romieu +6 more
2006Journal of Clinical Oncology13 citations
Semantic Scholar
Parcours de femmes 2001
D. Serin, J. Dilhuydy, P. Romestaing, N. Guiochet +4 more
2004ONCOLOGIE12 citations
Semantic Scholar
Final results of the RAPP-01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high-risk node negative and limited node positive (≤3) breast cancer patients.
E. Brain, M. Debled, J. Eymard, T. Bachelot +4 more
20098 citations
Semantic Scholar
Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).
P. Kerbrat, I. Desmoulins, L. Roca, C. Lévy +17 more
2017European Journal of Cancer7 citations
Semantic Scholar
[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].
A. Hardy-Bessard, R. Delva, X. Pivot, M. Espié +9 more
2012Bulletin du Cancer7 citations
Semantic Scholar
Randomized Multicentric Study of Perioperative Chemotherapy With Mitoxantrone in Early Breast Cancer
T. Petit, C. Borel, S. Theobald, D. Serin +4 more
2003Annals of Surgical Oncology7 citations
Semantic Scholar
Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study
S. Baffert, P. Cottu, Y. Kirova, F. Mercier +15 more
2013BMC Health Services Research6 citations Open access
Semantic Scholar
High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer
E. Brain, C. Lévy, D. Serin, Henri Roché +11 more
2011British Journal of Cancer6 citations Open access
Semantic Scholar
Long median survival with capecitabine (X) single-agent therapy for patients (pts) with anthracycline- and taxane-pretreated metastatic breast cancer (MBC).
R. Largillier, P. Fumoleau, C. Clippe, V. Diéras +6 more
2006Journal of Clinical Oncology5 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

H. Roche×13
Invite
H. Roche — researcher profile on SciRah
P. Kerbrat×13
Invite
P. Kerbrat — researcher profile on SciRah
P. Fumoleau×11
Invite
P. Fumoleau — researcher profile on SciRah
M. Campone×9
Invite
M. Campone — researcher profile on SciRah

×9

Invite

G. Romieu — researcher profile on SciRah

M. Spielmann×8

Invite

M. Spielmann — researcher profile on SciRah

Invite

M. Rios — researcher profile on SciRah

Invite

J. Canon — researcher profile on SciRah

Invite

T. Delozier — researcher profile on SciRah

Invite

A. Monnier — researcher profile on SciRah

Anne-Laure Martin×7

Invite

Anne-Laure Martin — researcher profile on SciRah

Invite

T. Bachelot — researcher profile on SciRah